Paper Details

  1. Home
  2. Paper Details

Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth.

Author: ColeR A, GentaR M, GrahamD Y, KarttunenT J, al-AssiM T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Azithromycin was more effective than metronidazole in a triple therapy for Helicobacter pylori infection, with a significantly higher cure rate with the 250-mg-t.i.d.-azithromycin dosage regime compared to the 250-mg-b.i.d.-dosage regime. However, the higher dosage regime was associated with more troublesome side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Azithromycin is new acid-stable macrolide that achieves 10- to 40-fold higher tissue levels than erythromycin after oral dosing. Important to note, the tissue half-life of azithromycin is measured in days instead of hours. METHOD: We evaluated two new triple therapies for Helicobacter p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7872278

データ提供：米国国立医学図書館（NLM）

Azithromycin Triple Therapy for Helicobacter pylori Infection: A New Frontier in Eradication

Helicobacter pylori (H. pylori) infection is a common cause of peptic ulcer disease. This research delves into the efficacy of azithromycin-based triple therapy for H. pylori eradication. The study evaluated two new triple therapy regimens in which azithromycin was substituted for metronidazole, combined with tetracycline and bismuth subsalicylate. The authors investigated the effectiveness of azithromycin at different dosages, aiming to identify a regimen that is both effective and tolerable.

Azithromycin: A Potential Replacement for Metronidazole

The study found that azithromycin-based triple therapy was effective in eradicating H. pylori infection, but the success rate varied depending on the dosage. The higher dosage of azithromycin (250 mg t.i.d.) resulted in a significantly higher eradication rate compared to the lower dosage (250 mg b.i.d.). The study also noted that a significant proportion of patients receiving the higher dosage experienced troublesome side effects.

Optimizing Azithromycin Therapy for H. pylori Eradication

This research provides valuable insights into the potential of azithromycin-based triple therapy for H. pylori eradication. The study highlights the need for further research to identify the optimal dosage and regimen to maximize efficacy while minimizing side effects. Just as a camel needs to find the right balance of water and food in the desert, patients with H. pylori infection need to find the right balance of treatment effectiveness and tolerability.

Dr.Camel's Conclusion

This study provides a promising glimpse into the potential of azithromycin for H. pylori eradication. The findings suggest that azithromycin may be a viable alternative to metronidazole, but further research is needed to optimize its use. The study emphasizes the importance of continued research and innovation in the field of H. pylori therapy, paving the way for more effective and tolerable treatment options.

Date :
  1. Date Completed 1995-03-30
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

7872278

DOI: Digital Object Identifier

7872278

Related Literature

Article Analysis
・Side Effects of bismuth subsalicylate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.